EL7.AI
Mergers & AcquisitionsMedium•19 November 2026•
4 min read

Unable to Confirm Standard BioTools Shareholder Approval of Treeline Deal on November 19

Key Facts

1The result of the shareholder vote at the meeting scheduled for November 19, 2026, could not be verified.
2Former Standard BioTools shareholders were expected to own 16% of the combined entity, compared with 84% for Treeline shareholders.
3LAB shares closed at $0.57 on November 18, 2026.

It could not be verified whether Standard BioTools shareholders approved the proposals to merge with Treeline Biosciences and sell the mass cytometry business, the outcome scheduled for a special meeting on November 19, 2026. The meeting agenda included votes on share issuance, a charter amendment and incentive plans, as well as the business sale, according to the proxy statement filed with the U.S. Securities and Exchange Commission. The vote results on these proposals therefore remain unconfirmed in the available open sources. The deal terms published before the meeting describe an all-stock merger between the two companies. EL7 data showed that the company’s shares, which trade under the ticker LAB, closed at $0.57 on November 18, 2026.

Under the expected ownership structure upon completion of the merger, former Standard BioTools shareholders were expected to own about 16% of the combined entity, compared with about 84% for former Treeline shareholders. The percentages remain subject to adjustment based on net cash at closing, according to the terms announced by Standard BioTools. This allocation means Treeline shareholders would hold the larger stake in the resulting company, while Standard BioTools shareholders would retain a minority stake. The agreement also provided for the distribution of one contingent value right for each share outstanding before the merger, entitling its holder to potential payments tied to net proceeds from certain legacy assets. These rights are tied to completion of the deal under the announced terms and do not represent guaranteed cash consideration at closing.

For the sale of the mass cytometry business, the agreement with Element set cash consideration of $5.5 million, payable at closing and subject to customary adjustments. The company’s disclosure says the sale is expected to close at approximately the same time as the merger, while the proxy statement said completion of the sale is not a condition to completion of the merger. This means the two transactions are linked in timing but do not necessarily depend on closing together. Standard BioTools initially agreed to sell the business to Multiplex Bio on July 28, 2026, then terminated that agreement and announced a replacement agreement with Element on September 30. The change in buyer followed an unsolicited takeover offer from GMT Venture on August 29, which the company deemed a superior offer, according to company disclosures.

The proxy statement also disclosed that the company received 15 demand letters from purported shareholders between July 27 and November 9, 2026, seeking additional information about disclosures related to the deal. This was before the special meeting scheduled for November 19, which was held virtually, according to the document. It also said Treeline would be the accounting acquirer, and its historical financial statements would replace those of Standard BioTools in public filings after completion of the merger. This arrangement establishes the accounting basis for the combined entity after closing, but does not by itself establish the vote result or completion of the deal. After completion of the merger and the name change to Treeline Biosciences, the shares were expected to trade on Nasdaq under the ticker TRLN.

The company said in its initial announcement that completion of the merger was expected in the second half of 2026, subject to regulatory approvals, Standard BioTools shareholder approval and customary closing conditions. The proxy statement later estimated the expected timing as the fourth quarter of 2026 and set March 31, 2027, as the outside date after which either party could elect to terminate the agreement if the deal had not closed. Completion therefore remains subject to satisfaction of the specified conditions and procedures, and holding the meeting alone does not establish that they have been met. The process includes regulatory approvals and closing conditions, as well as the shareholder vote result, which could not be verified here. The proxy statement also expected the sale of the mass cytometry business to Element to close at approximately the same time as the merger, while the sale’s closing remained nonessential to completion of the merger.

Open on chart